Galien Golden Jubilee Forum USA 2021

Oct. 28th, 2021
8AM – 9AM

In-person registrationLive broadcast registration

MaryAnne Rizk, Chief Strategy Officer, Medable

Robert Califf, Head of Clinical Policy & Strategy, Verify and Google Health; Adjunct Professor, Duke University & Stanford University; former FDA Deputy Commissioner to President Barack Obama
Tony Clapsis, Vice President, CVS Clinical Trial Services
Cristina Duran, Chief Digital Health Officer, R&D, AstraZeneca
Sebastian Guth, President of Bayer Pharmaceuticals, Americas Region
Michelle Longmire, Co-founder & CEO, Medable
Andy Plump, President, Research & Development, Takeda Pharmaceuticals Company Ltd.


MaryAnne Rizk, PhD
Chief Strategy Officer

Dr. Rizk is leading the transformation charge in expanding global partner and innovation ecosystems for the modernization of digital trials. With more than 20 years of experience, Dr Rizk has been managing partnerships to accelerate clinical development across her career in technology (Oracle, Medidata), pharmaceutical (Merck), and clinical research organizations (IQVIA). She is a global digital advisor working with C-Suite leaders to determine strategic collaborations by leveraging leading cloud SaaS platforms, AIML, advanced analytics, connected devices to establish the high value impact for patients and accelerating drug/device developments. Dr.Rizk was was awarded with the 2021 PharmaVOICE 100 most inspiring leaders as a leading change agent. She earned her PhD, Masters and Bachelor of Engineering at Stevens Institute of Technology where she also is an adjunct professor. Dr Rizk also serves on a number of advisory boards including the Galien Foundation Digital Advisor, HBA and SCRS. She is based in NJ where she enjoys cycling and boating with her kids.

Robert Califf
Head of Clinical Policy & Strategy, Verify and Google Health;
Adjunct Professor, Duke University & Stanford University;
Former FDA Deputy Commissioner to President Barack Obama

Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health for Verily and Google Health. Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.

Tony Clapsis
Vice President
CVS Clinical Trial Services


Cristina Duran
Chief Digital Health Officer R&D

Digital Health takes a scientific, evidence-based approach – harnessing the power of artificial intelligence, data science and digital technology – to improve patient outcomes and experience.

Cristina has worked in AstraZeneca for 11 years, holding global roles across R&D, commercial, finance and country roles.

Prior to joining AstraZeneca, Cristina worked in the communications and high tech industry for several years, leading large transformation programmes, including new JV set up for large corporations and  leading business transformation

Cristina is passionate about innovation and increasing enterprise value, through inspiring an organisation to change for the future. Chartered Accountant (CIMA), which focus on board level strategic decision making.

Cristina is Spanish, enjoys running and oil painting, married with 2 children.

Sebastian Guth, PhD
Bayer Pharmaceuticals, Americas Region

Sebastian Guth leads Bayer’s Pharmaceuticals business in the Americas Region, including the United States, Canada, and Latin America. Prior to that, he served as Executive Vice President and Chief Marketing Officer for Bayer’s global Pharmaceuticals business. Previously, Guth served as President & Chief Executive Officer of Bayer Yakuhin Ltd., Osaka, leading Bayer’s healthcare business in Japan.

Guth started his career in the pharmaceuticals industry with Schering AG, where he held senior roles in Asia and the Middle East. Guth was later appointed Head of Strategy and Business Development for Schering’s European business. Following Bayer’s acquisition of Schering in 2006, he served as Chief Executive Officer of Bayer Turkey, Istanbul, and was Senior Representative of the Bayer Group in Turkey.

Guth completed his studies at the WHU Otto Beisheim Graduate School of Management in Germany. He earned his doctorate in Management Sciences from Berlin University of Technology in Germany. Guth lives with his wife and three children in New Jersey.

Michelle Longmire
Co-founder & CEO

Dr. Michelle Longmire is the founder and Chief Executive Officer of Medable. Dr. Longmire is mission driven to accelerate the development of new therapies for disease. As a Stanford-trained physician-scientist, Dr. Longmire identified critical barriers to drug development and founded Medable to pioneer a new category of clinical trial technologies that remove traditional roadblocks to participation and radically accelerate the research process. Medable is now the industry leader in decentralized and direct-to-patient research, serving patients in clinical trials in over 30 languages, 40 countries, and across all therapeutic areas. In addition to having raised over 40 million dollars in venture capital and driving Medable to an industry-leading position, Dr. Longmire has received recognition as a leading innovator and business woman, including being named as one of the 100 most creative people in business by Fast Company.

Andy Plump
President, Research & Development
Takeda Pharmaceuticals Company Ltd.

Andrew Plump, MD, PhD is the president of Research & Development at Takeda and serves as a member of the company’s board of directors. Early in his tenure Dr. Plump orchestrated a multi-year strategic and cultural transformation that has resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to build an exciting and sustainable early development and research pipeline, founded on strong translational science as well as platform capabilities in cell therapy, gene therapy and data sciences. Prior to Takeda, Dr. Plump served as head of Research & Translational Medicine, deputy to the president of R&D at Sanofi. Prior to Sanofi, Dr. Plump served as worldwide cardiovascular research head at Merck. Dr. Plump has been recognized for his contributions to the healthcare industry, education and the arts. He serves on several not-for-profit boards including the board of directors of the PhRMA Foundation, the Sarnoff Cardiovascular Research Foundation and the Biomedical Science Careers Program. He also serves in advisory board positions at BioCentury and the Boston Symphony Orchestra. Dr. Plump received his MD from the University of California, San Francisco, his PhD in cardiovascular genetics at Rockefeller University and his BS from MIT.